Market Research Logo

The Worldwide Market for Cancer Diagnostics, 3rd Edition

220 Pages Kalorama Information March 01, 2008 SKU: KLI1393082
Attention: There is an updated edition available for this report.

Who are the major players in testing for the number two killer in the world? What revenues can companies competing in this market expect in the next five years? How will the impact of trends such as an increased role of pharmacodiagnostics, the use of multiplex assays and a new emphasis on service products influence cancer diagnostics?

These questions and more are answered in Kalorama Information's Worldwide Market for Cancer Diagnostics, 3rd Edition. This report contains detailed market data on the following areas of cancer diagnostics:

  • Histology/Cytology
  • Immunoassays
  • Flow Cytometry
  • Rapid Tests
  • Molecular Assays
  • Tissue Arrays
  • Circulating Tumor Cells
  • Pharmacodiagnostics
Diagnostic tests for effective cancer screening are obviously needed more than ever. As cancer becomes more treatable, diagnostics are finding multiple expanded roles, including pharmacodiagnostics for matching the targeted treatment to the patient and ongoing disease monitoring as treatable cancer enters the realm of the chronic disease. Kalorama Information's Worldwide Market for Cancer Diagnostics, 3rd Edition represents the third time Kalorama has engaged in an exhaustive study on the status of this important diagnostic market. Among the market data provided in this report, readers will find:
  • Pap Smear Testing Volumes
  • DNA Reagents for Cancer Testing
  • CTC Testing Markets
  • Major Protein and Molecular Markers Used in Tissue Staining
  • Microarray Markets in Clinical Labs
  • Lists of Vendors and Major Products

This report includes detailed market analysis of the following screening tests:

  • DR-70
  • HAAH
  • The Cancer Profile
  • CTC
  • Fecal Occult Blood
  • PSA
  • H. pylori
  • IHC
  • ISH
As well as tests for specific cancers:
  • Bladder Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colon Cancer
  • Lung Cancer
  • Ovarian Cancer
  • Prostate Cancer

This latest edition of Kalorama’s study takes a fresh look at all of these developments both qualitatively and quanititatively. The report provides revenue and growth forecasts through 2012 and, as in the previous edition, analyzes the market in two ways:

  • Tests for specific cancers, and
  • Cancer tests in specific IVD segments
This allows the reader to match his or her own situation to the market at large.

In addition to extensive reviews of products on the market and in development in each segment, the report also provides the most extensive review of innovative companies yet compiled in this market with profiles of over 150 companies active in the segment.

Kalorama's diagnostics industry analyst Shara Rosen provides the rigorous analysis and thoughtful research that has been made her market reports the backbone of diagnostic market decision-making for years.

The following companies were profiled in this report:

  • 20/20 GeneSystems Inc.
  • 454 Life Sciences Corporation
  • A&G Pharmaceutical
  • AdnaGen AG
  • Affymetrix Inc.
  • Agendia B.V.
  • Agilent Technologies Inc.
  • Alethia Biotherapeutics Inc.
  • Almac Diagnostics (formerly ArraDx)
  • Althea Technologies, Inc.
  • Ambrilia Biopharma Inc.
  • AMDL, Inc.
  • American Diagnostica Inc.
  • Aperio Technologies, Inc.
  • Applied Genomics, Inc. (AGI)
  • Applied Imaging Corp./Genetix
  • Asuragen, Inc.
  • AsymmetRx, Inc.
  • AviaraDx (formerly Arcturus Biosciences)
  • AVIVA Biosciences Corporation
  • BioCurex, Inc.
  • BioGenex Laboratories, Inc.
  • BioImagene, Inc.
  • Biomoda, Inc.
  • BioMosaics
  • BioNanomatrix
  • Biophysical Corp.
  • BioServe
  • Biosite Incorporated
  • BIOVIEW, Inc.
  • Bostwick Laboratories, Inc.
  • Bruker BioSciences Corporation
  • CCC Diagnostics LLC
  • Cancer Genetics, Inc.
  • Cangen Biotechnologies, Inc.
  • Celera
  • Celerus Diagnostics
  • Cellumen, Inc.
  • CeMines, Inc.
  • ChemSensing
  • Clarient Inc. (formerly ChromaVision)
  • CombiMatrix Molecular Diagnostics (CMDX)
  • CompuCyte Corporation
  • Correlogic Systems, Inc.
  • CytoCore, Inc. (formerly Molecular Diagnostics, Inc.)
  • Cytyc Corporation
  • Dako A/S
  • diaDexus Inc.
  • DiaGenic ASA
  • DiagnoCure
  • Diamics, Inc.
  • Digene Corporation (Acquired by Qiagen)
  • DNA Direct, Inc.
  • DxS
  • eGene Inc.
  • Epigenomics AG
  • EXACT Sciences Corporation
  • eXagen Diagnostics, Inc.
  • Exiqon A/S
  • Falcon Genomics, Inc.
  • Fermiscan Holdings Limited (FER)
  • Fluidigm Corporation
  • Fujirebio Diagnostics. Inc. (FDI)
  • GeneNews Limited (formerly ChondroGene Limited)
  • GenoMed, Inc.
  • Genomic Health
  • Genoptix Inc.
  • Gen-Probe Incorporated
  • Genzyme Corporation
  • Greiner Bio-One International AG
  • Gynecor
  • Health Discovery Corporation
  • HistoRx, Inc,
  • Ikonisys Inc.
  • Illumina
  • ImmunArray Ltd.
  • Immunicon Corporation
  • Immunotope, Inc.
  • InterGenetics, Inc.
  • Invirion Diagnostics, LLC
  • Ipsogen
  • Kronus Inc.
  • Laboratory Corporation of America Holdings (LabCorp)
  • Luminex Corporation
  • MacroArray Technologies, LLC
  • Matritech
  • MDS/Molecular Devices Corporation
  • Med BioGene, Inc. (MBI)
  • Menssana Research, Inc.
  • Micronics Inc.
  • Miraculins Inc.
  • Modern Technology Corp.
  • MolecularMD
  • MonoGen
  • Monogram Biosciences Inc. (formerly Virologic, Inc.)
  • mtm laboratories AG
  • Myriad Genetics, Inc.
  • NeoMatrix, LLC
  • NorChip
  • NorDiag ASA
  • Nuvera Biosciences
  • Olympus Life and Material Science Europa, GMBH
  • Onco Detectors International LLC
  • Oncolab Inc.
  • OncoMethylome Sciences S.A.
  • Onconome, Inc. (formerly Tessera Diagnostics)
  • One Cell Systems, Inc.
  • Orion Genomics
  • Oxford Genome Sciences Ltd. (OGeS)
  • OXIS International
  • Pacific Edge Biotechnology Ltd. (PEB)
  • Panacea Pharmaceuticals, Inc.
  • Pathwork Diagnostics (formerly Predicant Biosciences)
  • Perceptronix Medical Inc.
  • PerkinElmer, Inc.
  • Perlegen Sciences, Inc.
  • PersonaDX
  • Power3 Medical Products, Inc.
  • Precision Therapeutics
  • Predictive Biosciences
  • PreMD Inc.
  • Primagen Holding B.V.
  • Proteome Systems Limited
  • Provista Diagnostics (formerly Biomarker Technologies LLC)
  • Qiagen N.V.
  • Quest Diagnostics Incorporated
  • RainDance Technologies, Inc. (RDT)
  • Rational Therapeutics
  • Response Genetics, Inc.
  • Rosetta Genomics Ltd.
  • Rubicon Genomics, Inc.
  • Rules-Based Medicine, Inc.
  • Saladax Biomedical, Inc. (SBI)
  • Signet Laboratories, Inc.
  • Source MDx
  • Targeted Diagnostics & Therapeutics, Inc. (TDT)
  • Targeted Molecular Diagnostics, LLC (TDM)
  • Tripath Imaging, Inc.
  • Ventana Medical Systems. Inc.
  • Veridex, LLC
  • Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.)
  • Vision BioSystems Ltd/Danaher Corp.
  • Vitatex Inc.
  • Wako Chemicals USA
  • WaveSense LLC
  • Xenomics, Inc.
  • Xytos Inc.
  • Zila Inc.

License Note: Kalorama Information's listed default price on its information products reflects a single user license only. Purchasing a departmental license (up to 10 users at one location) or a global site license (entire company) permits multiple individuals in the company to benefit from this resource.

Show Full Description

Show Table of Contents

The Worldwide Market for Cancer Diagnostics, 3rd Edition

Kalorama Information
March 01, 2008

Search inside this report

Pricing & Delivery

Online Download
Hard Copy Mail Delivery
Departmental License (up to 10 users one location)
Global Site License
Online Download plus 1 Hard Copy

Didn't find what you are looking for?

Let us find it for you. One of our knowledgeable research assistants will work with you to find exactly the right research to answer your questions:

US: 800.298.5699 International: +1.240.747.3093 Or leave us a message and we'll call you back!

Receive bi-weekly email alerts for new market research.

CTA Image

Download our free eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download CTA

Share this report